Almac Group in the news

Cheryl Kole will become President and Managing Director of Almac Clinical Technologies on October 1, 2026, succeeding the retiring Valarie Higgins.

Almac's Charnwood campus celebrates 10 years of significant growth, exceeding job projections, expanding its service offerings, and continuing to invest in advanced pharmaceutical development and manufacturing capabilities.

Arran Chemical Company, a part of Almac Sciences for over a decade, will rebrand as Almac Sciences (Athlone) Limited from October 1, 2026, to unify its identity without altering operations or legal status.

Arran Chemical Company will rebrand as Almac Sciences, integrating more clearly into the parent company's offerings while maintaining all existing operations and services.

Galen, Almac Group's commercial division, introduced Galsana, a new global brand for medical nutrition products aimed at patients with rare metabolic diseases.

Almac Group, a pharmaceutical services company, donated 250,000 to 33 charities globally, including $13,000 each to three Triangle-based nonprofits selected by employees.

Almac Group donated over $300,000 to 33 global charities, including three Triangle-based nonprofits focused on child hunger, anti-racism, and youth mentorship.

Almac Group is projected to reach 5,791 employees worldwide by March 2026, a 6.2% increase from 2023.

This podcast series by Almac Clinical Services details the complex journey of clinical trial supplies from planning and strategy to global distribution, quality control, and patient delivery.

Almac Group has raised $339 million over 15 funding rounds, with 6 institutional investors participating.

Almac Trial Coordinator is an eClinical orchestration solution that unifies various functions to streamline complex clinical trials.

Almac Group achieved record-breaking financial results with £1.1 billion in revenue and a 16% increase in pre-tax profit.

Almac Group reported record revenues of 1.1 billion and a 16% increase in profit, reaching 138.9 million for the year ended September 30, 2025, while expanding its global workforce to over 7,900.

Almac Group achieved record annual revenues of £1.1bn and a 16% profit increase while expanding its global workforce to 8,000 people.

Record financial results show revenue hitting £1.1 billion and profits rising 16% amid ongoing global expansion.

Almac Group achieved record-breaking annual revenue of £1.1 billion and increased its global workforce to 7,900 as part of a sustained multi-year capital investment strategy.

A new white paper details how SDS-PAGE provides robust residual protein detection and quality control for biocatalytic API manufacturing.

Comprehensive pharmaceutical development services now include a validated SDS-PAGE method for precise residual protein determination in complex drug manufacturing environments.

Almac Group is expanding its Clinical Services team in Derry/Londonderry with new project management and distribution roles.

A new market research report identifies Almac Group as a major player in the global clinical trial supply and logistics market, forecasting trends and opportunities through 2033.